Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Conditions

• BCR-JAK2 Fusion Protein Expression
• Blasts 20 Percent or Less of Peripheral Blood White Cells
• Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
• Blasts More Than 5 Percent of Peripheral Blood White Cells
• Blasts Under 20 Percent of Bone Marrow Nucleated Cells
• Chronic Eosinophilic Leukemia, Not Otherwise Specified
• Eosinophilia
• Hepatomegaly
• Hypereosinophilic Syndrome
• JAK2 Gene Mutation
• Splenomegaly
• TEL-JAK2 Fusion Protein Expression

Interventions

• DRUG: Ruxolitinib

Sponsor

William Shomali

Collaborators

• [object Object]